title: [Comparative studies on the value of acute phase proteins and CA-125 for monitoring patients with ovarian cancer].
abstract: In a study of 71 patients with malignant ovarian tumors serum levels of CA-125, C-reactive protein (CRP), alpha-1-antitrypsin and coeruloplasmin were analysed. In contrast to the tumor-free group significantly higher values of CA-125, CRP and alpha-1-antitrypsin were found in the group with recurrent disease. However, the serum-concentrations of coeruloplasmin remained unchanged in both groups. In the group with progressive disease the median values of CA-125 were greater than 65 U/ml and of CRP greater than 12 micron/ml, respectively. The median serum concentrations of alpha-1-antitrypsin (2 to 4 mg/ml) and coeruloplasmin (150 to 600 ng/ml) did not reach their cut-off levels. Beside CA-125 the analysis of CRP and alpha-1-antitrypsin is an additional helpful procedure for the monitoring of patients with malignant ovarian tumors.
authors: II. Universitäts-Frauenklinik Wien.
authors: H
authors: H
authors: Kölbl
authors: G
authors: G
authors: Tatra
authors: K
authors: K
authors: Schieder
authors: C
authors: C
authors: Bieglmayer
mesh_terms: D000209:Acute-Phase Proteins / Q000032:analysis*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis*; D002097:C-Reactive Protein / Q000032:analysis; D002570:Ceruloplasmin / Q000032:analysis; D003536:Cystadenocarcinoma / Q000032:analysis; D004715:Endometriosis / Q000032:analysis; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000032:analysis*; D000515:alpha 1-Antitrypsin / Q000032:analysis
chemical_list: D000209:Acute-Phase Proteins; D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; D000515:alpha 1-Antitrypsin; D002097:C-Reactive Protein; D002570:Ceruloplasmin
vernacular_title: Vergleichende Untersuchungen über die Wertigkeit von Akute-Phase-Proteinen und CA-125 für das Monitoring von Patientinnen mit Ovarialkarzinom.